Abstract 8044: Clopidogrel versus Aspirin for Maintenance Monotherapy After Percutaneous Coronary Intervention: An Updated Meta-Analysis with 10-Year Follow-Up Data
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.8044 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Danielle Voltani und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Long-term antiplatelet monotherapy after percutaneous coronary intervention (PCI) remains an important strategy for secondary cardiovascular (CV) prevention following completion of dual antiplatelet therapy (DAPT). However, American Heart Association (AHA) guidelines favor aspirin, diverging from the European Society of Cardiology (ESC) guidelines, which increasingly support clopidogrel. Given the publication of three recent studies, including two extended follow-up analyses, we performed an updated meta-analysis comparing clopidogrel versus aspirin monotherapy after PCI to evaluate their comparative efficacy and safety profiles.
Methods
A systematic literature search was conducted in PubMed, Embase, and the Cochrane Library from inception through May 7, 2026, for RCTs and observational studies evaluating clopidogrel versus aspirin as maintenance monotherapy after completion of DAPT following PCI. Studies were included if they reported comparative CV or bleeding outcomes in adult patients undergoing PCI treated with clopidogrel or aspirin monotherapy after a defined period of DAPT. Statistical analyses were performed using Review Manager 5.4 and Stata 19. For comparative analyses, pooled effect estimates were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I 2 statistic, while pooled estimates were calculated using a random-effects model with the Restricted Maximum Likelihood (REML) method for effect size estimation.
Results
Nine studies (5 observational studies and 4 RCTs; N = 48,666; mean follow-up time of 4.3 years) were included. Baseline characteristics were similar between groups, with predominantly male patients with a mean age of 65.1 years and high prevalences of acute coronary syndrome, hypertension, diabetes mellitus, dyslipidemia, and prior myocardial infarction. Clopidogrel monotherapy was associated with a lower risk of major adverse CV events (MACE) (HR: 0.82 CI 0.74-0.92; p
Zitieren
APA
Voltani, D., Pinto, F. G., & Talavera, J. A. (2026). Abstract 8044: Clopidogrel versus Aspirin for Maintenance Monotherapy After Percutaneous Coronary Intervention: An Updated Meta-Analysis with 10-Year Follow-Up Data. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.8044
Vancouver
Voltani D, Pinto FG, Talavera JA. Abstract 8044: Clopidogrel versus Aspirin for Maintenance Monotherapy After Percutaneous Coronary Intervention: An Updated Meta-Analysis with 10-Year Follow-Up Data. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.8044
BibTeX
@article{Voltani2026,
author = {Voltani, Danielle and Pinto, Felipe Guimaraes and Talavera, Juan Armando},
title = {Abstract 8044: Clopidogrel versus Aspirin for Maintenance Monotherapy After Percutaneous Coronary Intervention: An Updated Meta-Analysis with 10-Year Follow-Up Data},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.8044}
}
EUVIMED